Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery

Table 1 Clinical data (n = 62)

	n (%)
Median age (range; yr)	22.0 (4-34)
Parity before surgery
0	48 (77.4)
1	8 (12.9)
2	6 (9.7)
Presentation
Pelvic mass	24 (38.7)
Abdominal pain	18 (29.0)
Abdominal distension	15 (24.2)
Others1	5 (8.1)
Tumor side
Right	34 (54.8)
Left	26 (41.9)
Bilateral	2 (3.2)
Detail of FSS
Unilateral SO	49 (79.0)
Unilateral cystectomy	4 (6.5)
Unilateral SO & cystectomy	9 (14.5)
Frozen section	26 (41.9)
Cytology
Not done	23 (37.1)
Negative	29 (46.8)
Positive	10 (16.1)
Omentectomy
Not done	18 (29.0)
Negative	40 (64.5)
positive	4 (6.5)
Lymphadenectomy
Not done	32 (51.6)
Negative	26 (41.9)
Positive	4 (6.5)
Appendectomy	32 (51.6)
Surgical outcome
No residual	47 (75.8)
Optimal	5 (8.1)
Suboptimal (residual tumor > 1 cm)	10 (16.1)
Histology
Dysgerminoma	17 (27.4)
Immature teratoma	20 (32.3)
Yolk sac tumor	15 (24.2)
Mixed type	5 (8.1)
Others2	5 (8.1)
Stage
I	46 (74.2)
II	6 (9.7)
III	7 (11.3)
IV	3 (4.8)
Adjuvant chemotherapy
None	19 (30.6)
BEP	42 (67.7)
EMACO	1 (1.6)
Cycles of chemotherapy
1-3	6
4-6	33
> 6	4
Long-term side effect
None	46 (74.2)
Numbness	3 (4.8)
Lung fibrosis	2 (3.2)
High-frequency hearing loss	1 (1.6)
Tinnitus	1 (1.6)
Progression of disease	4 (9.5)
Death	5 (8.1)
Alive	55 (88.7)
Missing data	2 (3.2)

¹Others: Amenorrhea (2), anti-NMDAR (N-methyl D-aspartate receptors) encephalitis (1), incidental finding during cesarean section (1), and hyperthyroidism (1).

²Others: Struma ovarii (1), carcinoid (1), chorioCA (1), steroid cell tumor (1), and papillary thyroid CA arising in teratoma (1).

Death: SN 43, 52, 74, 108, and 110. SO: Salpingo-oophorectomy; BEP: Bleomycin etoposide cisplatin; EMACO: Etoposide methotrexate actinomycin D cyclophosphamide vincristine.